NKGN Stock Chart & Stats
$0.06
$0.02(4.11%)
At close: 4:00 PM EST
$0.06
$0.02(4.11%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.33
Previous CloseN/A
Volume116.73K
Average Volume (3M)5.29K
Market Cap
$7.84M
Enterprise Value$46.02M
Total Cash (Recent Filing)$6.00K
Total Debt (Recent Filing)$38.19M
Price to Earnings (P/E)―
Beta-1.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding130,602,230
10 Day Avg. Volume5,077
30 Day Avg. Volume5,291
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap5.87
Enterprise Value/Revenue70.59
Enterprise Value/Gross Profit141.18
Enterprise Value/Ebitda2.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NKGen Biotech News
NKGN FAQ
What was NKGen Biotech’s price range in the past 12 months?
NKGen Biotech lowest stock price was <$0.01 and its highest was $0.33 in the past 12 months.
What is NKGen Biotech’s market cap?
NKGen Biotech’s market cap is $7.84M.
When is NKGen Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NKGen Biotech’s earnings last quarter?
Currently, no data Available
Is NKGen Biotech overvalued?
According to Wall Street analysts NKGen Biotech’s price is currently Overvalued.
Does NKGen Biotech pay dividends?
NKGen Biotech does not currently pay dividends.
What is NKGen Biotech’s EPS estimate?
NKGen Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NKGen Biotech have?
NKGen Biotech has 130,602,230 shares outstanding.
What happened to NKGen Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NKGen Biotech?
Currently, no hedge funds are holding shares in NKGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NKGen Biotech
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company’s autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Technical Analysis
Ownership Overview
― Insiders
―
Mutual Funds
2.11% Other Institutional Investors
97.89% Public Companies and
Individual Investors